Introduction {#S1}
============

Posttransplant lymphoproliferative disease (PTLD) constitutes a heterogeneous group of lymphoproliferative disorders occurring as severe complications of immunosuppression after solid organ transplantation (SOT). Acquired by up to 15% of pediatric transplant recipients, most cases of childhood PTLD are of B-cell origin and associated with Epstein--Barr virus (EBV) infection or reactivation ([@B1], [@B2]). Long-lasting immunosuppressive therapy to prevent graft rejection as well as lack of EBV-specific immunity at the time of transplantation contribute to the high incidence and unfavorable prognosis of PTLD in children ([@B1]). Up to 20% of affected patients eventually succumb to the disease ([@B1]). While modulation of immunosuppressive therapy may be sufficient in some patients, multi-agent immuno-/chemotherapy serves as the primary treatment option for advanced stage PTLD in children resulting in 80% overall survival ([@B3]). In the PTLD-1 study, complete response to Rituximab conferred a favorable outcome in adults ([@B4]). Central nervous system (CNS) PTLD displays an unfavorable outcome with 30--50% overall survival (isolated disease) ([@B5]--[@B7]) and as low as 0--10% (combined systemic and CNS disease) ([@B7], [@B8]). For these high-risk patients, very limited treatment options are available. Intrathecal rituximab as a combination to intravenous immuno-/chemotherapy is a promising treatment option ([@B9]). In addition, transfer of EBV-specific T-cell lines manufactured from healthy volunteers has shown promise in some patients with CNS involvement ([@B10]). Here, we report the first case of treatment of an SOT patient with CNS PTLD receiving freshly isolated, partially HLA-matched EBV-specific T-cells (EBV-CTLs) from an unrelated third party donor in addition to intravenous and intrathecal chemo-/immunotherapy.

Methods {#S2}
=======

Ethical Approval and Patient Informed Consent {#S2-1}
---------------------------------------------

The study was approved by the IRB of Hannover Medical School. The patient's legal guardian gave written informed consent to both participation in the research project and publication of the case report.

Donor Pre-Testing, Production of EBV-CTLs, and Application {#S2-2}
----------------------------------------------------------

Frequencies of EBV-CTLs were determined in patient mother's blood (not sufficient for transfer) as well as in five partially HLA-matched potential donors from the alloCELL T-cell donor registry ([www.alloCELL.org](www.alloCELL.org), Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) as described using EBV peptide pools EBV nuclear antigen 1 (ppEBNA-1) and EBV Select (ppSelect) (Miltenyi Biotec, Bergisch-Gladbach, Germany) ([@B11]).

###### 

Donor selection: HLA characteristics and verification of donor's Epstein--Barr virus (EBV)-specific memory T cells.

            Donor type   HLA-type   HLA match   IFN-γ EliSpot (spw/2.5 × 10^5^ PBMCs)   IFN-γ CSA \[% IFN-γ CD3^**+**^ T cells\]                                           
  --------- ------------ ---------- ----------- --------------------------------------- ------------------------------------------ ------- ------ ---- ------ ----- ------ -------
  Patient                03         07/14       07/08                                   01/15                                      05             0    1      /     /      /
  Mother    PMRD                                                                                                                                  0    16     10    0.04   4.26
  TPD 1     PMUD         03/11      07          07                                      15/16                                      05/06   5/10   23   TNTC   108   1.25   48.35
  TPD 2     PMUD         03         07          07                                      15                                         06      5/10   3    8      3     0.01   5.28
  TPD 3     PMUD         03         07          07                                      15                                         03/06   5/10   5    61     13    0.09   56.35
  TPD 4     PMUD         03/11      07          07                                      15                                         06      4/10   35   120    114   0.04   16.36
  TPD 5     PMUD         03         07/18       07                                      12/15                                      06/07   5/10   32   162    141   0.21   68.85

*For EliSpot assay and CSA, EBV-specific T cells were activated by 4 h *in vitro* restimulation with peptide pools EBNA1, Select and both in combination (EBNA1 + Consensus), respectively. TPD, third party donor; PMRD, partially matched related donor; PMUD, partially matched unrelated donor; HLA, human leukocyte antigen; IFN-γ, interferon-gamma; spw, spot per well; CSA, cytokine secretion assay; OF, original fraction, before enrichment; TCF, T-cell fraction, after magnetic enrichment; TNTC, too numerous to count*.

###### 

T-cell receptor CDR3 sequences of clones displayed in Figures [3](#F3){ref-type="fig"}A,B.

  cdr3 clones selectively detected in T cell product (donor = D) and post transfer   cdr3 clones detected in recipient (R) before transfer and post transfer                                                                                                   
  ---------------------------------------------------------------------------------- ------------------------------------------------------------------------- ------------ -------------------------- ---------- -------------------- ----------------------- --------------------------------
  EBNA.D1                                                                            CASSSKRQVPDTQYF                                                           Select.Dl    CASSPRQADEQFF              EBNA.R1    CASSDDFFSHTDTQYF     Select.Rl               CASSDDFFSHTDTQYF
  EBNA.D2                                                                            SSARDGDLRGQFF                                                             Select.D2    CSVGQAAYEQYF               EBNA.R2    CASSLTGRTVTDTQYF     Select.R2               CASSLTGRTVTDTQYF
  EBNA.D3                                                                            CSAPGQVQETQYF                                                             Select.D3    CSAPGQVQETQYF              EBNA.R3    CASSRVGAANEQFF       Select.R3               CASSRVGAANEQFF
  EBNA.D4                                                                            CASSFASGGSSYNEQFF                                                         Select.D4    CASSPSGVPGANVLTF           EBNA.R4    CASSFRDRQDYEQYF      Select.R4               CATSPGVEQYF
  EBNA.D5                                                                            CASSLRGTEAFF                                                              Select.D5    CASSLLQGADTEAFF            EBNA.R5    CASSQDLAGGLLSYEQYF   Select.R5               CASSLEGPGYNEQFF
  EBNA.D6                                                                            CASSLEGDRHQHF                                                             Select.D6    CASSPVRSSETQYF             EBNA.R6    CASSNTDTQYF          Select.R6               CASNNLPGLETQYF
  EBNA.D7                                                                            CASSLERDRPQHF                                                             Select.D7    CASSLPTGGYYEQYF            EBNA.R7    CATSPGVEQYF          Select.R8               CASSPSRNTEAFF
  EBNA.D8                                                                            CASSAGPATNEKLFF                                                           Select.D8    CASSLSYEQYF                EBNA.R8    CAISKRLFSYNEQFF      Select.RS               CASSFRDRQDYEQYF
  EBNA.D9                                                                            CASSTTDTQYF                                                               Select.D9    CASNKLPGLETQYF             EBNA.R9    CSARDGDLRGQFF        Select.R9               CAISKRLFSYNEQFF
  EBNA.D10                                                                           CASSQFGGNTIYF                                                             Select.D10   CASSVRASPLHF               EBNA.RI0   CASSQDRGRSPLHF       Select.Rl0              CASSQTSGDGDTQYF
  EBNA.D11                                                                           CASNVGYSRPDNEQFF                                                          Select.D11   CASSLRTGELFF               EBNA.R11   CASRTPSGGAWETQYF     Select.Rll              CASSQDPSAEQFF
  EBNA.D12                                                                           CASSLSGAYEQYF                                                             Select.D12   CASSLVTNEQFF               EBNA.R12   CASSYRLGRLNQPQHF     Select.R12              CASSQGRDNSYEQYF
  EBNA.D13                                                                           CASSLGGDRPQHF                                                             Select.D13   CASSHQGGGQMRTGELFF         EBNA.R13   CASSSGIFNYGYTF       Select.R13              CASSGDIPTEHRDTQYF
  EBNA.D14                                                                           CSAPGQVRETQYF                                                             Select.D14   CAWRETGGEVSEQYF            EBNA.R14   CASSPSRNTEAFF        Select.R14              CASRTPSGGAWETQYF
  EBNA.D15                                                                           CASSWEGDRPQHF                                                             Select.D15   CASSPPGGGDQETQYF           EBNA.R15   CASSSGTGFQETQYF      Select.R15              CASSQDLAGGLLSYEQYF
  EBNA.D16                                                                           CASSLEGDRPQHC                                                             Select.D16   CASKRGGNTEAFF              EBNA.R16   CASSYLRIARPDYGYTF    Select.R16              CASSNTDTQYF
  EBNA.D17                                                                           CSVGEQYI                                                                  Select.D17   CASSQETGSYEQYF             EBNA.R17   CAWSPGFTEAFF         Select.R17              CASSSGIFNYGYTF
  E8NA.D18                                                                           CASSHDSSDEQYF                                                             Select.D18   CASSEAVPGHQNTEAFF          EBNA.R18   CASSDPRGHEQYF        Select.R18              CASSYRLGRLNQPQHF
                                                                                                                                                               Select.D19   CASSSGDEQYF                EBNA.R19   CASSEEELDNNQPQHF     Select.R19              CASSSGTGFQETQYF
                                                                                                                                                               Select.D20   CASSVSEGNTIYF              EBNA.R20   CASSFETGGTGELFF      Select.R20              CSARDGDLRGQFF
                                                                                                                                                               Select.D21   CASSLTGFLNTEAFF            EBNA.R21   CASSQAWYSGNTIYF      Select.R21              CASSQDRGRSPLHF
                                                                                                                                                               Select.D22   CASSFSRDWNTEAFF            EBNA.R22   CSVEVENRNTEAFF       Select.R22              CASSDPRGHEQYF
                                                                                                                                                               Select.D23   CAVNGGQFSGNTIYF            EBNA.R23   CASSPGQHNSPLHF       Select.R23              CAWSPGFTEAFF
                                                                                                                                                               Select.D24   CASTFRMRPQDTQYF            EBNA.R24   CSARPRGQPYEQYF       Select.R24              CASSFETGGTGELFF
                                                                                                                                                               Select.D25   CSAPGRVQETQYF              EBNA.R25   CASSQDPSAEQFF        Select.R25              CASSYLRIARPDYGYTF
                                                                                                                                                               Select.D26   CASSRDKAYEQYF              EBNA.R26   CASNNLPGLETQYF       Select.R26              CASSPGQHNSPLHF
                                                                                                                                                               Select.D27   CASTFRMLPQDAQYF            EBNA.R27   CASSIVNEAFF          Select.R27              CASSEEELDNNQPQHF
                                                                                                                                                               Select.D28   CASS F PAVGLPSSSYN EQF F                                   Select.R28 Select.R29   CASSQAWYSGNTIYF CSARPRGQPYEQYF

Manufacturing of clinical-grade EBV-specific CD4+ and CD8+ T-cells from EBV-seropositive allogeneic 5/10 HLA-matched third party donor (TPD 1, Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) was performed on a CliniMACS device using ppEBNA1 and ppSelect in combination and the IFN-γ Cytokine Capture System (Miltenyi Biotech). Quality control of the final T-cell product was done as described ([@B11]). Details on the T-cell manufacturing and product can be found in the Supplementary Material. The patient got one fresh and four cryopreserved EBV-specific T-cell products from a single manufacturing process.

Monitoring {#S2-3}
----------

Monitoring of viral load and EBV-specific T-cell frequencies in patient's blood was done before and after T-cell transfer by IFN-γ ELISpot assay as described and using the following peptide pools: ppEBNA1, ppSelect, ppLMP2a, ppBZLF1 (all Miltenyi Biotec) ([@B12], [@B13]). If suitable numbers of PBMCs were obtained, EBV-CTLs were expanded over 7 days using the respective antigens ppEBNA1 and ppSelect in TexMACS media (Miltenyi Biotec) containing 50 U/ml IL-2 (Peprotec). After 7 days, IFN-γ ELISpot assay was repeated using the respective antigens. Expanded cells were used for TCR beta chain repertoire analysis.

TCR Beta Chain Repertoire Analysis {#S2-4}
----------------------------------

The stimulated and expanded PBMCs were stained with following antibodies: dead/alive (DAPI), hCD45^+^ (APC-Vio770), hCD3^+^ (PE-Cy7), hTCR αβ^+^ (FITC), and hCD8^+^ (VioGreen). They were sorted into CD8^+^ T-cells with a FACS Aria Fusion flow cytometer. mRNA was extracted using the RNeasy Plus Micro Kit (QIAGEN) and then reverse-transcribed into cDNA according to the SMARTer RACE 5′-3′ PCR Kit (Clontech) manual. Then, a combined amplification of the TCR β CDR3-region and Illumina adaptor sequences were performed with the Advantage 2 PCR Kit (Clontech). After a DNA sample size identifying gel electrophoresis, the bands were extracted with the Gel extraction Kit (QIAGEN). Indexing of the samples was performed with Nextera Primer Kit (Illumina) in another Advantage 2 PCR and the product was purified with the Agencourt AMPure XP Kit. The DNA concentration was measured with the Qubit 2.0 fluorometer, samples were pooled, and the pool was set to 4 nM. Denaturation and dilution of the pool was done as described at the Illumina MiSeq Dilution and Denaturation Guide. Finally, next generation sequencing (NGS) was performed on the Illumina MiSeq System. For the analysis, the FastQ files were annotated at IMGT/HighV-Quest database and processed with tcR-package and VDJtools.

Case Presentation {#S3}
=================

An 11-year-old boy with Alagille syndrome received a related liver allograft during first year of life. Being EBV-negative at transplantation, seroconversion occurred 2 years later. Initial immunosuppression was based on tacrolimus, followed by a combination with mycophenolate mofetil. Ten years after transplantation, he suffered from severe headache, nausea, vomiting, and phono-/photophobia without B symptoms. Funduscopic examination revealed bilateral papilledema. Magnetic resonance imaging (MRI) studies of the brain demonstrated multifocal lesions in the left hemisphere (Figure [1](#F1){ref-type="fig"}A). After initial treatment for suspected toxoplasmosis, biopsy of the lesion revealed a monomorphic EBV-associated PTLD with features of a diffuse large B-cell lymphoma without *MYC* translocation (Figure [1](#F1){ref-type="fig"}B). Immunohistochemistry showed expression of CD20 and CD30. Most lymphoma cells expressed EBERs (Epstein--Barr encoded RNAs), LMP1 (EBV latent membrane protein 1), and LMP2a while EBNA2 (Epstein--Barr nuclear antigen 2) and BZLF1 (EBV immediate-early protein) were detected in a low number of neoplastic cells (Figure [1](#F1){ref-type="fig"}C). EBV PCR was negative in cerebrospinal fluid and weakly positive in peripheral blood (\<1,000 copies/ml). Therefore, the diagnosis of EBV-related primary CNS PTLD was made.

![Posttransplant lymphoproliferative disease (PTLD) characteristics and composition of third party donor Epstein--Barr virus (EBV)-specific T-cell product. TPD-derived EBV-CTLs were manufactured by the clinical-scale IFN-γ-based CliniMACS cytokine capture system (CCS) and used for adoptive T-cell transfer (ACT). **(A)** Contrast-enhanced sagittal T1-weighted magnetic resonance imaging images of the patient's central nervous system at diagnosis of PTLD. Images demonstrate multifocal hyperintense lesions in the left hemisphere in temporal, insular, and parietal lobe. **(B)** Histology of a brain lesion biopsy with staining for H&E and CD20. EBV-association was proven by EBER *in situ* hybridization. **(C)** Expression of EBV products in the lymphoma. LMP1, LMP2a, EBNA2, and BZLF1 were stained by immunohistochemistry. **(D,E)** Composition of the EBV-specific T-cell graft. Proportion of leukocyte subsets and the percentage of IFN-γ secreting EBV-specific T cells were detected after 4 h of *ex vivo* stimulation with the GMP-grade peptide pools EBV ppEBNA1 and ppSelect by flow cytometry. **(D)** Fractions collected during the EBV-specific T-cell manufacturing process \[leukapheresis (LA), preselection (PreS), and positive fraction (PF)\] were assessed for the proportion of lymphocyte and leukocyte subsets including: CD3^+^ T-cells, CD19^+^ B cells, CD56^+^ NK cells, CD3^+^CD56^+^ NKT cells, CD3^−^CD56^+^ NK cells, CD33^+^ granulocytes, and CD14^+^ monocytes. The compositions of the different cell subsets in the fractions LA, PreS, and PFs are shown. **(E)** The frequencies (left *y*-axis) and numbers (right *y*-axis) of IFN-γ^+^ cells (×10^6^) within the CD3, CD4, and CD8 T-cell populations were analyzed in the PF of the CliniMACS CCS enrichment process to determine the efficiency of the process.](fimmu-09-01475-g001){#F1}

Total body imaging and bone marrow aspirate histology displayed no evidence for systemic disease. During initial treatment with dexamethasone, symptoms rapidly improved. Immunosuppression was stopped and immune-/chemotherapy was initiated with six doses of intravenous (i.v.) rituximab (375 mg/m^2^) and weekly intrathecal (i.th.) therapy with rituximab (40 mg), methotrexate (12 mg), cytarabine (30 mg), and prednisone (10 mg) over 10 weeks ([@B9]). A partial response by MRI was observed after 3 weeks evolving to complete remission at the end of immuno-/chemotherapy. Due to poor prognosis and the lack of EBV-specific T cells in the patient's peripheral blood, we decided to consolidate treatment by transfer of partially HLA-matched EBV-CTLs.

Results and Discussion {#S4}
======================

The patient received five doses of 2.5 × 10^4^ EBV-CTLs/kg body weight from a 5/10 HLA-matched third party donor (TPD; Table [1](#T1){ref-type="table"}). During the production process, CD3+ T-cells were enriched to \>80% in the T-cell product with a predominance of CD8+ T-cells (Figures [1](#F1){ref-type="fig"}D,E; Data Sheet S1 in Supplemental Material). T-cells were administered every 3 weeks in the absence of graft-versus-host disease. After the second injection, the patient developed a skin rash around the neck, which turned out to be atopic dermatitis on histology and responded well to topical steroids without recurrence after subsequent T-cell injections. No other acute or chronic side effects were observed. EBV-PCR remained negative in peripheral blood throughout the whole course. After the end of treatment, immunosuppression was re-introduced with everolimus. At the last follow-up, 2 years after end of cellular therapy, the patient is in continuous remission of PTLD with good organ graft function.

No EBV-CTLs were detectable in patient blood on two occasions before adoptive immunotherapy (Figure [2](#F2){ref-type="fig"}A). In contrast, EBV-CTLs against ppEBNA1 and ppSelect became immediately and constantly detectable 4 days after the first T-cell transfer. While total numbers of CD3+, CD4+, and CD8+ T-cells remained stable throughout the treatment course, EBV-CTLs increased to a maximum of 40 per 250,000 PBMC before the second adoptive transfer. Over time, the target antigens of T-cell response broadened from initially EBNA1 and ppSelect to a broader response including T-cells against LMP2a and BZLF1, respectively (Figure [2](#F2){ref-type="fig"}A). Since epitopes from these two proteins matching the patient's or donor's HLA-type are not contained in the peptide pools used for manufacturing, this suggests that transfer of EBV-specific TPD cells induced an endogenous EBV-directed immune response in the patient, which was absent prior to immunotherapy. Frequency of EBV-CTLs increased during a 7-day *in vitro* restimulation and expansion demonstrating proliferative capacity (Figure [2](#F2){ref-type="fig"}B).

![Adoptive T-cell therapy and patient follow-up. **(A)** Monitoring of patients' cellular immunity was performed with blood samples collected at different time points before and after adoptive T-cell transfer (ACT). Frequencies of CD3, CD4, and CD8 T-cells were assessed by flow cytometry following detection of the Epstein--Barr virus (EBV)-specific T-cell (EBV-CTL) repertoire in response to ppEBNA1, ppSelect, ppBZLF1, and ppLMP2a by using IFN-γ EliSpot. EBV copy numbers were determined in blood and stool samples by quantitative PCR. **(B)** *Ex vivo* expansion of EBV-CTLs. PBMCs were isolated at different time points after ACT \[white bars (before expansion, day 0)\] and restimulated with the premium-grade peptide pools ppEBNA1 or ppSelect over 7 days \[black bars (after expansion, day 7)\] followed by the assessment of the EBV-CTL response against ppEBNA1 and ppSelect by IFN-γ Elispot.](fimmu-09-01475-g002){#F2}

Occasionally, transferred cells could be detected in patient material after transfer, but most authors were unable to retrieve TPD cells on analysis ([@B14]). We aimed at dissecting EBV-directed T-cell responses in the T-cell graft and the patient on a clonal molecular level. We performed TCR beta chain (TRB) repertoire analyses by NGS to follow-up the transferred cells and to monitor their expansion to EBV-associated antigens. Investigating the 77 shared clonotypes 41 were identified as expanding clones in CD8+ T cells after the transfer (Figures [3](#F3){ref-type="fig"}A,B). Four clones could be detected in both follow-up samples at 6 and 7 months after T-cell transfer, while the remaining 37 clones were picked up only once. Notably, the most abundant clone (EBNA.D8 = CASSAGPATNEKLFF, Figure [3](#F3){ref-type="fig"}A; Table [2](#T2){ref-type="table"}) in the enriched T-cell product was not recovered at high abundance while two other clones that made up only 0.001% each of the donor's CD8 + TRB sequences appeared to expand to 0.51 and 0.17% in two patient samples obtained 7 months after transfer (EBNA.D1 = CASSSKRQVPDTQYF; Select.D6 = CASSPVRSSETQYF, Figure [3](#F3){ref-type="fig"}A and Table [2](#T2){ref-type="table"}). These findings suggest that at least a fraction of the transferred TPD T-cells were expanding and presumably contributing to EBV-specific T-cell responses in the patient. At the same time, we observed a sustained EBNA1-specific expansion of endogenous TRB sequences that were already present in the recipient's CD8+ T-cell pool before TPD T-cell treatment (Figure [3](#F3){ref-type="fig"}B). This is consistent with the idea that exogenous T-cells stimulated an efficient endogenous anti-EBV T-cell response and may explain the finding that EBV-T-cell responses against unrelated antigens (LMP2, BZLF1) newly arise after T-cell transfer. Due to limited material availability, we performed the analyses on expanded cells after one *in vitro* peptide pool restimulation, which leaves the possibility of *ex vivo* TCR skewing. These limitations need to be considered in future clinical trials.

![TCR beta chain sequencing of Epstein--Barr virus-stimulated T-cells before and after adoptive transfer. TCR beta chain sequencing was performed on blood samples at different timepoints before and after adoptive T-cell transfer and on the input sample itself. The left panel shows the samples enriched by stimulation with the ppEBNA1 peptide pool, whereas the right panel shows the ones after stimulation with ppSelect. Expansion of different shared clones is shown in both panels for exogenous **(A)** and endogenous **(B)** origin. Clones are labeled according to the antigen, origin (D, donor; R, recipient) and number. TCR sequences can be found in Table S1 in Supplementary Material.](fimmu-09-01475-g003){#F3}

Prognosis of CNS PTLD is very poor with 30% overall survival ([@B7], [@B8]). We and others have reported successful administration of intrathecal rituximab; however, efficacy has not been validated in larger series ([@B9], [@B15]). Several studies and case reports show an effect of adoptive T-cell transfer in PTLD ([@B10], [@B16]--[@B19]). In particular, patients with CNS PTLD with poor outcome may benefit from this new treatment strategy ([@B8], [@B9]). Haque and colleagues reported responses in 3/5 patients with CNS PTLD after SOT using *in vitro* expanded EBV-specific TPD T-cell lines and lymphoma regression in CNS B-cell lymphoma in an immunodeficiency patient ([@B10], [@B20]). The efficacy of directly isolated EBV-CTLs in CNS PTLD after SOT is still unknown. Studies from patients after stem cell transplantation indicate that these cells are effective in CNS PTLD ([@B19]). In the case reported here, combined therapy with intrathecal chemotherapy and rituximab led to sustained complete remission of CNS PTLD. Transfer of partially HLA-matched EBV-CTLs provoked a robust anti-EBV T-cell response containing both exogenous and endogenous TRB signatures; the contribution of T-cell induction to ongoing remission remains uncertain.

Partially HLA-matched TPDs are an attractive source of virus-specific T-cells readily available if pre-screened and registered in T-cell donor registries ([@B13]). We did not observe any side effects of TPD T-cell transfer similar to other studies employing virus-specific T-cell therapy, which supports their feasibility and safety. Prospective studies are warranted to prove safety and efficacy of freshly isolated EBV-CTLs from TPDs in this vulnerable patient population.
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